A Study in Patients Reporting Cannabis Use Followed With an Application-Based Cannabis Journal

NCT07089225 | Not Yet Recruiting

• 2 other identifiers: 20250219.11005UG1CA189824
• Study Type: observational
• Target: 45
• Locations: 0 countries
• Sites: N/A

Brief Summary

This study is being done because there is a significant lack of data on the use of cannabis amongst cancer patients. The investigators believe that the collection of this data will help researchers and clinicians better understand the needs and the impact of cannabis use in this specific patient population.

Conditions

Cancer

Outcome Measures

Primary Outcomes (1)

• Cannabis Use

  In patients who report using cannabis, investigators will measure frequency and dose of cannabis and cannabinoid use, purpose of use (i.e., seeking recreational vs. medicinal effects), type (e.g., flower, concentrate, edibles), route of administration (e.g., smoking, vaping, ingestion, tincture, oil), psychoactive and non-psychoactive content (THC vs. CBD/CBG/CBN content in product), and products sources (from medical dispensaries and/or regulated adult-use stores).

  Enrollment + 6 months

Secondary Outcomes (1)

• Patient Reported Symptoms

  Enrollment + 6 months

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Oncology patients, receiving active therapy or in follow up following active therapy, and treated within the MaineHealth Cancer Care Network (MHCCN).

You may qualify if:

• Patients must be 18 years of age or older and able to give verbal informed consent to participate.
• Patients must be able to speak, read and understand English.
• Patients must report use of cannabis at time of study participation.
• Patients must have access to internet and ability to download Releaf™ App (MoreBetter, Ltd.) to a smartphone or tablet and must use Releaf™ App (MoreBetter, Ltd.) for cannabis journaling.
• Patients must be able to send and receive text messages, and be able to interact with web-pages on smartphone or tablet.
• There are 2 scenarios that patients are eligible for participation, and are listed below:
• Patients must have a cancer diagnosis for which they are receiving active therapy defined as follows:
• Surgery - must be within a 30-day pre- and/or post-operative (peri-operative) window if single modality of care. Patients must be 18 years of age or older and able to give verbal informed consent to participate.
• Radiation - must be within a 30-day pre- (simulation planning phase) and/or post-radiation window if single modality of care.
• Any anticancer systemic therapy including hormonal, biologic, targeted, and/or cytotoxic chemotherapy. Understandably, numerous patients recruited under surgery and/or radiation will receive systemic therapy as part of combined modality therapy, which is permissible. Regardless, all details regarding cancer diagnosis, stage, and treatment will be collected from the EMR, which will be detailed in the informed consent document.
• Any patient in follow-up by their primary oncology care provider and/or AYA and cardio-oncology survivorship clinic(s).
• All patients must be treated within the MHCCN thus ensuring access to clinical data in our system-wide EMR (Epic).
• Patients must obtain their cannabis either from a medical-use store, adult-use (recreational) store or both. Patients must obtain cannabis ONLY from medical/recreational stores. Illicit (or homegrown) sources are strictly prohibited.

Sponsors & Collaborators

• Scot Remick: lead
• National Cancer Institute (NCI): collaborator

MeSH Terms

Conditions

Neoplasms

Study Officials

• Scot Remick, MD

  MaineHealth

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Clinical Research Coodinator

CONTACT

207-550-1265; ntro@mainehealth.org

Research Program Manager

CONTACT

ntro@mainehealth.org

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR INVESTIGATOR
• PI Title: Oncology Research and Education Principal

Study Record Dates

• First Submitted: July 15, 2025
• First Posted: July 28, 2025
• Study Start: September 30, 2025
• Primary Completion (Estimated): August 30, 2026
• Study Completion (Estimated): December 31, 2026
• Last Updated: September 24, 2025

Record last verified: 2025-09